Cooper C L, Badley A D, Angel J B
Division of Infectious Diseases, Ottawa Hospital General Campus, Ottawa, Ontario;
Can J Infect Dis. 2001 May;12(3):157-63. doi: 10.1155/2001/542056.
Knowledge pertaining to hepatitis C virus (HCV)/human immunodeficiency virus (HIV) co-infection is currently incomplete or conflicting. Several points are well studied, however. Plasma HCV RNA levels are higher in matched HIV-infected people than in HIV-seronegative control subjects and are inversely correlated with CD4(+) T lymphocyte counts. HCV genotype does not appear to influence this value. Co-infected individuals develop histological and clinical features of HCV liver disease more rapidly than HIV-seronegative patients. Co-infected individuals appear to respond to interferon-alpha therapy equally as well as HIV-seronegative HCV-infected adults, but minimal information exists regarding the efficacy and toxicity of combination HCV therapy (interferon-alpha plus ribavirin) in this population. Adverse consequences of highly active antiretroviral therapy in co-infected patients include hepatic toxicity and, in a minority of patients, an 'immune restoration syndrome'. It is unclear whether long term, highly active antiretroviral therapy positively or negatively influences the natural history of HCV infection.
目前，关于丙型肝炎病毒（HCV）/人类免疫缺陷病毒（HIV）合并感染的知识尚不完整或存在争议。不过，有几点已得到充分研究。在匹配的HIV感染者中，血浆HCV RNA水平高于HIV血清阴性对照受试者，且与CD4(+) T淋巴细胞计数呈负相关。HCV基因型似乎不影响这一数值。合并感染个体比HIV血清阴性患者更迅速地出现HCV肝病的组织学和临床特征。合并感染个体对α干扰素治疗的反应似乎与HIV血清阴性的HCV感染成人相同，但关于该人群联合HCV治疗（α干扰素加利巴韦林）的疗效和毒性的信息极少。高效抗逆转录病毒疗法在合并感染患者中的不良后果包括肝毒性，少数患者还会出现“免疫重建综合征”。长期高效抗逆转录病毒疗法对HCV感染的自然病程是产生积极还是消极影响尚不清楚。
